Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Tuesday, FinViz reports. The brokerage presently has a $18.00 price objective on the biotechnology company’s stock, up from their prior price objective of $14.00. Deutsche Bank Aktiengesellschaft‘s price objective points to a potential upside of 4.41% from the company’s current price.
SRPT has been the subject of several other reports. HC Wainwright reiterated a “sell” rating and set a $5.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 5th. William Blair upgraded Sarepta Therapeutics to a “hold” rating in a research note on Wednesday, September 23rd. Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on Monday, September 28th. Finally, Robert W. Baird set a $18.00 price objective on shares of Sarepta Therapeutics in a research report on Friday. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $23.67.
Get Our Latest Report on Sarepta Therapeutics
Sarepta Therapeutics Trading Down 3.3%
Sarepta Therapeutics stock opened at $17.24 on Tuesday. Sarepta Therapeutics has a 52 week low of $14.68 and a 52 week high of $24.68. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The stock has a market capitalization of $1.82 billion, a P/E ratio of -12.58, a PEG ratio of 0.35 and a beta of 0.45. The stock has a 50-day simple moving average of $19.06 and a 200 day simple moving average of $18.62.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $381.35 million for the quarter, compared to the consensus estimate of $352.20 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. The business’s revenue was down 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) earnings per share. Analysts expect that Sarepta Therapeutics will post 3.27 earnings per share for the current year.
Institutional Investors Weigh In On Sarepta Therapeutics
Several hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in shares of Sarepta Therapeutics by 26.6% in the 1st quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock valued at $46,695,000 after purchasing an additional 450,336 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Sarepta Therapeutics during the 2nd quarter worth approximately $8,165,000. GSA Capital Partners LLP bought a new position in Sarepta Therapeutics in the 2nd quarter valued at approximately $1,862,000. Canada Pension Plan Investment Board bought a new position in Sarepta Therapeutics in the 2nd quarter valued at approximately $1,272,000. Finally, The Manufacturers Life Insurance Company bought a new position in Sarepta Therapeutics in the 2nd quarter valued at approximately $927,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches.
The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.
Sarepta is headquartered in Cambridge, Massachusetts.
Further Reading
- Five stocks we like better than Sarepta Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
